menu
    • menu
    [{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"SCD-044","moa":"S1P1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SPARC \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"8","companyTruncated":"SPARC \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"SPARC","sponsor":"Tripoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SPARC \/ Tripoint Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"SPARC \/ Tripoint Therapeutics"},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Phenobarbital Sodium","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SPARC \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"SPARC \/ Sun Pharmaceutical Industries Limited"}]

    Find Clinical Drug Pipeline Developments & Deals by SPARC

    Menu

    SPARC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SPARC

                            India arrow
                            AACR Annual meeting
                            Not Confirmed

                            SPARC

                            India arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenobarbital Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sun Pharma and SPARC Enter Into A License Agreement For Commercialization Of Phenobarbital For Injection In Th...

                            Details : SPARC’s phenobarbital sodium powder for injection is a benzyl alcohol and propylene glycol-free formulation intended for the treatment of seizures in neonates.

                            Product Name : Phenobarbital Sodium-Generic

                            Product Type : Controlled Substance

                            Upfront Cash : $10.0 million

                            September 11, 2022

                            Lead Product(s) : Phenobarbital Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SPARC

                            India arrow
                            AACR Annual meeting
                            Not Confirmed

                            SPARC

                            India arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levetiracetam

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Tripoint Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sparc Licenses Commercialization Rights of Elepsia Drug to Tripoint Therapeutics

                            Details : Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for ElepsiaTM XR 1000 mg and El...

                            Product Name : Elepsia

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 22, 2020

                            Lead Product(s) : Levetiracetam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Tripoint Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SPARC

                            India arrow
                            AACR Annual meeting
                            Not Confirmed

                            SPARC

                            India arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SCD-044

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : $145.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases

                            Details : Sun Pharma has been granted a worldwide licence for the development and commercialization of SCD-044, which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 cli...

                            Product Name : SCD-044

                            Product Type : Other Small Molecule

                            Upfront Cash : $20.0 million

                            May 29, 2020

                            Lead Product(s) : SCD-044

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : $145.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth